Benjamin Klausing, MD
Infectious Disease · Louisville, KYNPI 1851618102
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,587 of the $6,547 with a category attached, or 70.1%. Tetraphase Pharmaceuticals, Inc. accounts for 88.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $6,274 and has fallen 97.3% since, to $172 in 2025.
Across 45 payments — averaging $145.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tetraphase Pharmaceuticals, Inc.$6K
- Astellas Pharma US Inc$164
- Insmed, Inc.$141
- Phathom Pharmaceuticals, Inc.$120
- Gilead$111
- Viiv Healthcare Company$79
- plus $167 from 8 others
What the payments were for
- Speaking & faculty fees$4,58770%
- Travel & lodging$1,02116%
- Food & beverage$81312%
- Education$1262%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tetraphase Pharmaceuticals, Inc. | 9 | $5,766 |
| Astellas Pharma US Inc | 6 | $164 |
| Insmed, Inc. | 6 | $141 |
| Phathom Pharmaceuticals, Inc. | 1 | $120 |
| Gilead | 7 | $111 |
| Viiv Healthcare Company | 5 | $79 |
| Merck | 4 | $66 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Dynavax Technologies Corporation | 1 | $18 |
| Melinta Therapeutics, LLC | 1 | $17 |
| Cumberland Pharmaceuticals, Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
| AbbVie | 1 | $12 |
| Mayne Pharma Commercial LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,547 in reported general payments places this provider in the 80th percentile of 100 infectious disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 90 | $345,387 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $54,468 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 13 | $47,935 |
| PifeltroDoravirine | 14 | $21,130 |
| Vancomycin Hcl | 41 | $20,347 |
| Ampicillin Sodium | 23 | $6,702 |
| Daptomycin | 11 | $6,171 |
| CeftriaxoneCeftriaxone Sodium | 29 | $3,663 |
| Epinephrine | 13 | $2,209 |
| Doxycycline Hyclate | 22 | $942 |
| Cefadroxil | 33 | $747 |
| Amoxicillin | 13 | $407 |
| Acyclovir | 27 | $239 |
| Levofloxacin | 11 | $164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $111 | $399,854102 claims |
| Viiv Healthcare CompanyTriumeq | $79 | $47,93513 claims |
| MerckPifeltro | $66 | $21,13014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 100 infectious disease providers in Kentucky.
Other infectious disease in Louisville
- Julio RamirezLouisville$256K
- Martin GnoniLouisville$194K
- Paul SchulzLouisville$189K
- Tariq MehmoodLouisville$75K
- Anupama RaghuramLouisville$9K
- Barbara WojdaLouisville$7K
- Kamran AkhtarLouisville$4K
- Forest ArnoldLouisville$4K
- Mark BurnsLouisville$3K
- Kenechukwu ObiokoyeLouisville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.